首页> 外文期刊>Filaria journal >Mass ivermectin treatment for Onchocerciasis: Lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity
【24h】

Mass ivermectin treatment for Onchocerciasis: Lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity

机译:大规模伊维菌素治疗盘尾丝虫病:缺乏证据表明在共流行区对班氏乌氏杆菌的传播有附带影响

获取原文
           

摘要

There has long been interest in determining if mass ivermectin administration for onchocerciasis has 'unknowingly' interrupted lymphatic filariasis (LF) transmission where the endemicity of the two diseases' overlaps. We studied 11 communities in central Nigeria entomologically for LF by performing mosquito dissections on Anopheline LF vectors. Six of the communities studied were located within an onchocerciasis treatment zone, and five were located outside of that zone. Communities inside the treatment zone had been offered ivermectin treatment for two-five years, with a mean coverage of 81% of the eligible population (range 58–95%). We found 4.9% of mosquitoes were infected with any larval stage of W. bancrofti in the head or thorax in 362 dissections in the untreated villages compared to 4.7% infected in 549 dissections in the ivermectin treated villages (Mantel-Haenszel ChiSquare 0.02, P = 0.9). We concluded that ivermectin annual therapy for onchocerciasis has not interrupted transmission of Wuchereria bancrofti (the causative agent of LF in Nigeria).
机译:长期以来,人们一直在确定大量的伊维菌素治疗盘尾丝虫病是否“不知不觉地”中断了淋巴丝虫病(LF)传播,而这两种疾病的流行重叠。我们通过对按蚊LF媒介进行蚊子解剖研究了尼日利亚中部的11个社区的LF昆虫学。研究的社区中有六个位于盘尾丝虫病治疗区内,五个位于该区外。为治疗区内的社区提供了伊维菌素治疗长达两年,平均覆盖率达到合格人群的81%(范围为58-95%)。我们发现未经治疗的村庄中362个解剖中有4.9%的蚊子被头部或胸部的幼虫感染,相比之下,用伊维菌素处理过的村庄的549个解剖中有4.7%的蚊子被感染(Mantel-Haenszel ChiSquare 0.02,P = 0.9)。我们得出的结论是,依维菌素每年治疗盘尾丝虫病并未中断Wuchereria bancrofti(尼日利亚LF的病原体)的传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号